• 1. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 2. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
• 3. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 4. Aggregation-induced chiroptical generation and photoinduced switching of achiral azobenzene-alt-fluorene copolymer endowed with left- and right-handed helical polysilanes?
  Hailing Chen,Lu Yin,Meng Liu,Laibing Wang,Michiya Fujiki,Wei Zhang RSC Adv., 2019,9, 4849-4856
• 5. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazo[1,2-a]pyrimidines

Ethyl imidazo[1,2-a]pyrimidine-3-carboxylate (CAS No. 64951-07-1): A Versatile Scaffold in Modern Pharmaceutical Research

Ethyl imidazo[1,2-a]pyrimidine-3-carboxylate, identified by its chemical identifier CAS No. 64951-07-1, represents a significant molecular scaffold that has garnered considerable attention in the realm of pharmaceutical chemistry and drug discovery. This compound, belonging to the imidazopyrimidine class, exhibits a fused heterocyclic structure that combines the functionalities of both imidazole and pyrimidine moieties. Such structural features make it a promising candidate for further derivatization and exploration in various therapeutic applications.

The imidazo[1,2-a]pyrimidine core is a privileged scaffold in medicinal chemistry, known for its ability to interact with multiple biological targets. The presence of the ester group at the 3-position of the pyrimidine ring in Ethyl imidazo[1,2-a]pyrimidine-3-carboxylate introduces additional reactivity, allowing for diverse chemical modifications that can fine-tune its pharmacological properties. This versatility has made it a focal point in the development of novel bioactive molecules.

Recent advancements in computational chemistry and high-throughput screening have facilitated the rapid identification of potential drug candidates. Ethyl imidazo[1,2-a]pyrimidine-3-carboxylate has been utilized in virtual screening campaigns to identify compounds with inhibitory activity against various enzymes and receptors. Its structural motif is particularly relevant in the search for inhibitors of kinases, which are pivotal targets in oncology and inflammatory diseases.

In particular, studies have highlighted the scaffold's potential in developing treatments for cancer. The imidazopyrimidine moiety is known to exhibit kinase inhibition properties, making it a valuable building block for anticancer agents. Researchers have synthesized analogs of Ethyl imidazo[1,2-a]pyrimidine-3-carboxylate and evaluated their efficacy against different cancer cell lines. Some derivatives have shown promising results in preclinical studies, demonstrating significant cytotoxic effects while maintaining reasonable selectivity over normal cells.

The ester functionality in Ethyl imidazo[1,2-a]pyrimidine-3-carboxylate also provides a handle for further chemical manipulation. This group can be hydrolyzed to form a carboxylic acid or converted into other functional groups such as amides or thiols. Such modifications can enhance binding affinity or improve metabolic stability, critical factors in drug development. For instance, amide derivatives have been explored as protease inhibitors, leveraging the scaffold's ability to engage with specific enzymatic targets.

Another area of interest is the use of Ethyl imidazo[1,2-a]pyrimidine-3-carboxylate in designing molecules with antimicrobial properties. The fused heterocyclic system is capable of interacting with bacterial enzymes and DNA gyrase, making it a potential candidate for developing novel antibiotics. Recent research has demonstrated that certain derivatives exhibit broad-spectrum activity against Gram-positive and Gram-negative bacteria. This underscores the therapeutic potential of this scaffold beyond its application in oncology.

The synthesis of Ethyl imidazo[1,2-a]pyrimidine-3-carboxylate involves multi-step organic reactions that highlight its synthetic accessibility. Common synthetic routes include condensation reactions between appropriate precursors followed by functional group transformations to introduce the ester moiety. Advances in synthetic methodologies have enabled more efficient and scalable production processes, making it feasible to produce larger quantities for research purposes.

In conclusion, Ethyl imidazo[1,2-a]pyrimidine-3-carboxylate (CAS No. 64951-07-1) is a versatile and pharmacologically relevant scaffold with significant potential in pharmaceutical research. Its unique structural features and reactivity make it an attractive candidate for developing novel therapeutic agents targeting various diseases, including cancer and infectious disorders. Continued exploration and optimization of this scaffold are likely to yield valuable contributions to modern medicine.

• 1119452-82-2(Methyl imidazo1,2-apyrimidine-2-carboxylate)
• 64951-11-7(Imidazo[1,2-a]pyrimidine-3-carboxylic acid)
• 1339176-02-1(6-fluoro-Imidazo[1,2-a]pyrimidine-3-carboxylic acid ethyl ester)
• 62772-70-7(Ethyl 2-methylimidazo[1,2-a]pyrimidine-3-carboxylate)
• 76075-25-7(5,7-dimethyl-Imidazo[1,2-a]pyrimidine-2-carboxylic acid ethyl ester)
• 1339175-99-3(6-methyl-Imidazo[1,2-a]pyrimidine-3-carboxylic acid ethyl ester)
• 914219-93-5( )
• 90830-09-4(2,7-dimethyl-Imidazo[1,2-a]pyrimidine-3-carboxylic acid ethyl ester)
• 914219-81-1( )
• 64951-06-0(Ethyl imidazo[1,2-a]pyrimidine-2-carboxylate)